Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering

8 Sept 2021

Abstract excerpt

2 immunoglobulin G subclasses, blocked virus-receptor interactions, neutralized viral infection, and conferred complete protection against viral challenge. This new nanovaccine design framework might allow the rapid deployment of effective adjuvant-free phage-based vaccines against any emerging pathogen in the future.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to CRISPR and Genetic Engineering
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34516878
DOI: 10.1126/sciadv.abh1547

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineeringPMID 34516878Read ↗

Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseasesSemantic proximity Read ↗

Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and diseaseSemantic proximity Read ↗

Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design PlatformSemantic proximity Read ↗

Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2Semantic proximity Read ↗

Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and InfluenzaSemantic proximity Read ↗

T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target SpecificitySemantic proximity Read ↗

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2Semantic proximity Read ↗

Filamentous bacteriophages, natural nanoparticles, for viral vaccine strategiesSemantic proximity Read ↗

Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of ProteinsSemantic proximity Read ↗

Bacteriophage T4 nanoparticle capsid surface SOC and HOC bipartite display with enhanced classical swine fever virus immunogenicity: A powerful immunological approachSemantic proximity Read ↗

Computationally designed mRNA-launched protein nanoparticle vaccinesSemantic proximity Read ↗

Phage-based vaccinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.